Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Google Secures Pentagon AI Deal for Classified Projects 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
BURNABY, British Columbia, April 28, 2017 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference in Toronto, Canada on Tuesday, May 2, 2017 at 11:00 am ET.
A live audio webcast of the presentation will be available on the investors section of Xenon's website at www.xenon-pharma.com and will be available for replay following the event.
About Xenon Pharmaceuticals Inc.
Xenon is a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy. For more information, please visit www.xenon-pharma.com.
Investor/Media Contact: Jodi Regts Senior Director, Corporate Affairs Xenon Pharmaceuticals Inc. Phone: 604.484.3353 Email: [email protected]
